Ivan Tkáč

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Pharmacogenomic association between a variant in <scp> <i>SLC47A1</i> </scp> gene and therapeutic response to metformin in type 2 diabetes

Ivan Tkáč, Lucia Klimčáková, Martin Javorský et al. · Diabetes Obesity and Metabolism · 2012 · 112 citations

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas

Martin Javorský, Lucia Klimčáková, Zbyněk Schroner et al. · European Journal of Internal Medicine · 2011 · 92 citations

Molecular Pharmacology, Molecular Physiology, Molecular Pathway +7

The Severity of Coronary Atherosclerosis in Type 2 Diabetes Mellitus Is Related to the Number of Circulating Triglyceride-Rich Lipoprotein Particles

Ivan Tkáč, Brian P. Kimball, Gary F. Lewis et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1997 · 83 citations

Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes

Zbyněk Schroner, Martin Javorský, Ružena Tkáčová et al. · Diabetes Obesity and Metabolism · 2010 · 76 citations

Sulphonylurea Treatment, Metabolic Syndrome, Molecular Pharmacology +14